StockSaints Logo 

Dyax Earnings Preview

Dyax Company Logo Image

Dyax Corp. (DYAX)

Background: Dyax Corp., a biopharmaceutical company, engages in the identification, development, and commercialization of treatments for plasma kallikrein-mediated (PKM) angioedemas. It offers KALBITOR for the treatment of acute attacks of hereditary angioedema (HAE).

Dyax is anticipated to report modest second-quarter earnings after the market closes on July 24, 2013.

The consensus estimate is currently losing six cents a share, an improvement of 2 cents (%) from losing eight cents during the same period last year.
The lowest analyst estimate this report is losing eight cents per share, and the highest is losing five cents per share.

With short interest above 5%, investors will want to monitor changes to know if short sellers turn up the warning signals. Otherwise, the current 7.4% of the float short is relatively small and not a major concern.





Strong Buy



Moderate Buy



Avg Analyst Price Target




$56.30 million

$449.45 million

Est Low EPS



Est High EPS



1 Year Stock Price Change




Rate this article: 
Average: 5 (1 vote)
Stock Tickers: Author Disclosure: n/a